{"id":"vehicle-to-agn-199201","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AGN-199201 blocks NK1 receptors, which are involved in the transmission of pain signals, particularly in neuropathic and inflammatory pain pathways. By antagonizing these receptors, the drug aims to reduce pain perception without the systemic effects associated with opioid analgesics. This mechanism is particularly relevant for chronic pain conditions where substance P, the primary NK1 ligand, plays a key role in pain amplification.","oneSentence":"AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:32.590Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain"},{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT02595528","phase":"PHASE2","title":"A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-04-29","conditions":"Presbyopia","enrollment":163},{"nctId":"NCT02780115","phase":"PHASE2","title":"A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-05-26","conditions":"Presbyopia","enrollment":151},{"nctId":"NCT02132117","phase":"PHASE3","title":"Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06","conditions":"Erythema, Rosacea","enrollment":445},{"nctId":"NCT02131636","phase":"PHASE3","title":"Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Erythema, Rosacea","enrollment":440},{"nctId":"NCT01579084","phase":"PHASE1","title":"Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-04","conditions":"Rosacea, Erythema","enrollment":64},{"nctId":"NCT01735201","phase":"PHASE2","title":"AGN-199201 for the Treatment of Erythema With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-12","conditions":"Rosacea, Erythema","enrollment":357},{"nctId":"NCT02197806","phase":"PHASE2","title":"Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Presbyopia","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle to AGN-199201","genericName":"Vehicle to AGN-199201","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system. Used for Neuropathic pain, Chronic pain conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}